1. Introduction {#s0005}
===============

1.1. Background {#s0010}
---------------

In 2012, the World Health Organization (WHO) updated its recommendation on influenza vaccination of health workers (HWs) concluding that "HWs are an important priority group for influenza vaccination, not only to protect the individual and maintain health-care services during influenza epidemics, but also to reduce spread of influenza to vulnerable patient groups" [@b0005], [@b0010]. The *WHO Global Influenza Strategy (2019*--*2030)* reinforces this position by supporting countries to "develop and implement national, seasonal immunization policies for HWs and other high-risk groups" [@b0015].

In 2017, 96 of the 194 WHO Member States reported having policies in place for influenza vaccination of HWs [@b0020]. However, the Member States with such policies are unevenly distributed across WHO regions. Aside from mitigating seasonal influenza, influenza vaccine is considered the primary intervention to reduce mortality and morbidity in a severe pandemic. An efficient pandemic response depends largely on how well seasonal vaccine response to annual epidemics is embedded and implemented [@b0025].

*The Review Committee on the Functioning of the International Health Regulations (2005) in relation to Pandemic (H1N1) 2009* concluded that experience with comprehensive seasonal influenza programmes would provide valuable preparation in advance of a major pandemic [@b0030]. In November 2018, the Global Alliance for Vaccines and Immunization (GAVI) Board requested that the GAVI secretariat in collaboration with WHO assess the feasibility and impact of routine influenza immunization of HWs to support epidemic and pandemic influenza preparedness [@b0035].

To support these global considerations and considering the poor uptake of influenza vaccination in HWs despite the multiple reasons advocated for it as a policy, we conducted a *Rapid Evidence Appraisal* [@b0040]. We aimed to capture the breadth of available evidence on influenza in health care settings and the wider health impacts of influenza vaccination in HWs. We critically appraised the literature relating to: influenza risk to HWs and the risk they pose to their patients; the benefit of influenza vaccination in HWs; and influenza vaccine uptake in HWs. By including evidence relevant to multiple stakeholders collectively - HWs, patients, and their employers -- we holistically evaluated the evidence in the most policy-relevant framework as possible.

2. Methods {#s0015}
==========

2.1. Systematic literature search {#s0020}
---------------------------------

*General Search Approach*: The search objective was to examine the evidence under three topics using a Rapid Evidence Appraisal approach. Each topic gave rise to 2 or 3 questions for query (*see* [Table 1](#t0005){ref-type="table"}). Evidence was queried from MEDLINE, EMBASE, CINAHL, Cochrane CENTRAL, Cochrane Reviews, WHO Global Index Medicus, National Health Service (NHS) Evidence, NHS HTA database, and multiple international clinical trials' registries. We executed three independent searches by topic with distinct search terms to capture literature for all topic questions. *Search terms* followed the PICO framework (population, intervention, comparators, outcomes) and studies were selected based on pre-determined criteria.Table 1Rapid Evidence Appraisal topics, queried questions, number of studies selected, and their associated references.TopicDescriptionQuestionsTotal Studies cited/questionRefs.1The Impact of HW Influenza Vaccination on HWs and their employers1.What is the evidence that HWs are at an increased risk of influenza infection compared to the general population?7[@b0055], [@b0060], [@b0065], [@b0070], [@b0075], [@b0080], [@b0085]2.What is the evidence that vaccinating staff in healthcare settings against influenza reduces influenza in HWs, absenteeism and/or the wider economic impact of influenza in the healthcare workforce?14[@b0055], [@b0090], [@b0095], [@b0100], [@b0105], [@b0110], [@b0115], [@b0120], [@b0125], [@b0130], [@b0135], [@b0140], [@b0145], [@b0150]  2The Impact of HW Influenza Vaccination on their patients1.What is the evidence that HWs transmit influenza (asymptomatic or symptomatic) to inpatients in healthcare settings?11[@b0155], [@b0160], [@b0165], [@b0170], [@b0175], [@b0180], [@b0185], [@b0190], [@b0195], [@b0200], [@b0205]2.Does influenza vaccination of HWs provide a protective effect for inpatients in healthcare settings?6[@b0055], [@b0125], [@b0210], [@b0215], [@b0220], [@b0225]3.*If so, what number or proportion of HWs needs to be vaccinated to provide this effect?*8[@b0055], [@b0210], [@b0230], [@b0235], [@b0240], [@b0245], [@b0250], [@b0255]  3Influenza Vaccine Uptake in HWs- hurdles and solutions1.What is the evidence for successful practical interventions to increase HW vaccine uptake of influenza vaccine?11[@b0055], [@b0125], [@b0260], [@b0265], [@b0270], [@b0275], [@b0280], [@b0285], [@b0290], [@b0295], [@b0300]2.What is the state of knowledge in sociological, behavioural, and public health policy research on influenza vaccine uptake in HWs?3[@b0055], [@b0305], [@b0310]

*Study Types* varied by review topic and question but generally included experimental or observational studies, systematic reviews, controlled observational studies, and randomized controlled trials (RCTs). Due to the volume of evidence for *Topic 3 (HW vaccine uptake)*, literature was restricted to systematic reviews, RCTs, and evidence-based policy guidelines or toolkits. *Study Outcomes* were limited to laboratory-confirmed influenza as a primary outcome measure, when relevant to the queried question. Other outcomes included sickness absence incidence and/or duration, economic or productivity costs due to illness, influenza-like- illness (ILI) or respiratory illness, the number needed to vaccinate (NNV), and vaccination uptake in HWs.

*Study Selection, exclusion and inclusion:* Studies were selected and extracted onto a standardized template by 3 reviewers (DJ, HM, KM∋) independently, defaulting to a third party (JSN-V-T) as needed. Study selection followed the following process: remove duplicates and unrelated content by title; review abstracts - remove unrelated content, descriptive studies, commentaries, or studies that clearly do not meet the inclusion/exclusion criteria defined for each question; review full text - exclude based on exclusion/inclusion criteria or remove studies that lack a clear study design, methodology, or results section. Studies were then ranked according to the Maryland Scientific Methods (SMS) Quality Scale [@b0045] with 1 being the lowest and 5 being the highest [@b0050]. We limited the inclusion of studies to those scoring 2--5 on the quality scale published from 2006 to 2018 in whole or in summary in the English language.[2](#fn2){ref-type="fn"}

2.2. Data handling {#s0025}
------------------

*Data Extraction*: Two reviewers (DJ, KM) executed the search strategy and results were independently screened by three reviewers (DJ, HM, KM) for eligibility using a three-stage sifting approach of title, abstract and full-text. The two reviewers for 2006--2016 (DJ, HM) literature reached consensus on which search hits met the criteria for inclusion at each stage (including exclusion at the full-text stage). Any disagreements were resolved by discussion or involvement of an additional reviewer.

*Data analysis*: Detailed characteristics of included studies were captured and descriptively summarized in tables and figures identifying study design, population, setting, measured outcomes, results, and limitations (See [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}).Table 2Rapid Evidence Appraisal included studies and their characteristics for **Topic 1 - Questions 1&2.***StudyMaryland Quality Score and classificationStudy DesignCountrySettingIncluded Studies/or Population type\# of participantsIntervention or FocusOutcomesAre HWs at a greater risk than the general population Yes/No*Dini [@b0055]4\
High\
ModerateReviewMixedHospital2 systematic reviews/ 28 included address this question29,358 subjectsH1N1pdm09\
vaccineLab-confirmed influenza infectionYes for H1N1pdm09Ip [@b0060]2\
Low\
ModerateOS- RCHong KongHospitalInpatient and outpatient health workers∼ 6000H1N1pdm09 risk and impactAll cause or Acute Respiratory Illness\
Related Sickness Absenteeism during influenza epidemicsYes during 2009\
Inconclusive with seasonal influenzaCooley [@b0065]No Score-Model\
SimulationPandemic Simulation\
ModelUSAHospitalSimulation of influenza epidemic and the impact on hospital-based HWsN/ASeasonal\
vaccineSecondary attack rate of pandemic influenza among unprotected HWs.Yes, for pandemic influenzaBellei [@b0520]2\
Low\
ModerateOS -PCBrazil-Outpatients\
-CommunityOutpatient health workers, outpatients with acute respiratory infection, renal-transplant patients203 HWs\
140 community\
69 renal-transplantN/ALab-confirmed influenza rates by population, clinical symptoms, and risk factor.Inconclusive, but vaccination may have confounded resultsYiannakoulias [@b0075]3\
ModerateOS-Retrospective\
CCCanada-Province-wide assessment using billing dataMedical professionalsExposure to ILI in a patientFrequency of exposure to patient with ILI in 7 days prior to ILI diagnosis in case providers vs. matched control providersYes, but can't make a clear connection between exposure and ILI using billing dataSartor [@b0080]2\
Low\
ModerateOS -PCFranceInternal Medicine WardInpatients and health workers23 patients and 22 HWsN/AAttack rate of influenza A among patients and HWsYes, but patients also at risk during an outbreakElder [@b0085]2\
Low\
ModerateOS - CSScotlandAcute care hospitalsInpatient health workers with regular patient contact518N/ASerologically-confirmed influenza.\
Proportion of asymptomatic infection (recall + serology)Yes\
for asymptomatic infection  Imai [@b0090]5SR and *meta*-analysisMixed13 studies total\
3 RCTs, 2PC, 8RCN = 20,282;\
5,083 vaccinated\
15,199 notSeasonal\
Vaccine onlyPooled n = RR, Lab-confirmed flu, ILI, absenteeism, mean difference, cost-effectiveness**Does vaccine benefit HWs or their employers?**\
**Yes/No**HighYesDini [@b0055]4\
High\
ModerateReviewMixed6 systematic reviews relevant to this question/ 28 studiesDidn't poolInfluenza\
VaccineLab-confirmed flu, ILI, absenteeismYesGianino [@b0100]2\
Low moderateOS-RCItalyHospitalHospital health workers∼ 5000Seasonal\
vaccineAbsenteeism during influenza epidemic periodsYesPereira [@b0105]3\
ModerateOS- RCEngland223 health trusts each seasonHospital, primary care, inpatient, outpatient, specialist∼800,000Seasonal\
vaccineSickness absence rate, Relationship between sickness absence rate and uptakeYesFrederick [@b0125]3\
ModerateOS-RCUSAHospitals & OutpatientHealth workers∼3000Mandatory\
vaccine policyIncidence/length of absenteeism mandatory vs. non-mandatory sitesYes  *StudyMaryland Quality Score and classificationStudy DesignCountrySettingIncluded Studies/or Population type\# of participantsIntervention or FocusOutcomesDoes vaccine benefit HWs or their employers?*\
*Yes/No*Riphagen-Dalhuisen [@b0140]4\
High\
ModeratecRCTThe Netherlands6 Tertiary Medical CentresAll hospital HWs during 2009--2011HWs = all fromMulti-faceted uptake intervention for H1N1pdm09 and seasonal vaccineVaccine uptake; absenteeism rates among HWs in December of each yearNo to absenteeism, actually saw an increaseHui [@b0150]4\
High\
ModerateRCTMalaysiaFaculty of DentistryStaff/students of the faculty of Dentistry Control.Control = 176\
Vaccinated = 179Seasonal\
VaccineFollow up over a 4-month period from vaccination, via questionnaire to ascertain self-reported outcomes: ILI prevalence; Recurrence of ILI; Visits to doctor due to ILI; Family members or housemates reporting ILI, Days of absenteeism due to ILI, Fever days due to ILIYes, to all self-reported outcome measuresNguyen- VanTam [@b0115]2\
Low moderateOS- RC-TSEnglandTeaching Hospital, multiple wardsHWs -- non-medical staff (nurses/ porters); nursing staff from admissions, intensive therapy and surgical; porters dealing with supplies and wasteN = 271N/AIndividual sickness absence contrasted epidemic/ non-epidemic periods in season. Measured: Total time lost/person as % of rostered time.\# weeks/ person which absence occurred '92-'93 season non-epidemic yr. comparison, since low flu activityNoAtamna [@b0130]3\
ModerateOS-PCIsraelMedical CentreHealth workers, vaccinated vs. non-vaccinated during flu seasons and not733 vaccinated 908 not (199 in flu season)Seasonal VaccineRates of PCR confirmed influenza A infection in vaccinated vs. non vaccinated HWsinconclusiveNjuguna [@b0110]2\
Low moderateOS-PCKenya5 Hospitals with influenza surveillanceHealth Workers who were offered free vaccine3803H1N1pdm09\
vaccineVaccine effectiveness in vaccinated vs unvaccinated HCP: Incidence of acute respiratory illness, absenteeism from work due to respiratory illness laboratory-confirmed influenza (using PCR)No, actually increased absenteeismSaadeh-Navarro [@b0135]2\
Low moderateOS-RCMexicoTeaching HospitalVaccinated HWs (health care worker defined as all personnel with patient contact)N = 3636Seasonal influenza\
vaccineA reduction in ILI, Absence due to ILI\
Total days of work lostYesFujita [@b0120]2\
Low moderateOS-RCJapanUniversity hospitalNursing Staff1680Seasonal\
vaccineVaccine effectiveness through self-reported fever and cold-like symptoms.\
Days absent.YesPreaud [@b0145]No Score\
Economic\
ModelEM8 European CountriesAll health workers for those countriesMixed HWsN/ASeasonal\
trivalent vaccineNumber of influenza-related events averted (cases, GP visits, hospitalisations, deaths and days of work lost) at current vaccination coverage rates.Yes, to cases avertedParlevliet [@b0155]No Score\
Cost-Benefit\
AnalysisCBAThe NetherlandsHospitalsHealth workers6251Seasonal\
vaccineRetrospective cost-benefit model as employer's perspective to see costs and benefits. For vaccine programs as workplace absenteeism.Yes, To cost benefit to employers[^2]Table 3Rapid Evidence Appraisal included studies and their characteristics for **Topic 2 - Questions 1 -- 3.**StudyMaryland Quality Score and classificationStudy DesignCountrySettingIncluded Studies/ or Population typeIntervention or Focus\# of participantsOutcomesDo HWs transmit influenza to patients? Yes/NoVoirin [@b0155]4\
High\
ModerateOS-PCFranceGeriatric\
HospitalGeriatric patients\
Nurses, doctors, contacts in geriatric settingWearable sensors for 12 dayspatients (n = 37) nurses (n = 32), doctors (n = 15) contacts (n = 18,765)Sensor data combined with lab-confirmed Influenza A, B, phylogenetic analyses -track transmissionYesEibach [@b0160]3\
ModerateOS-RCFranceGeriatric Ward -Acute CareGeriatric patients and HWs tested for fluMolecular-based subtypingPatients (n = 66)\
HWs (n = 57)Nosocomial influenza transmission confirmed with molecular and epidemiologic testingYesVanhems [@b0165]3\
ModerateOS-PCFranceHosptial in flu season -- Acute CarePatients and HWsExposure- contagious personsPatients (n = 21,519)\
HWs (n = 2,153)RR of hospital-acquired ILI based on source contacts, lab-confirmed influenzaYesVanhems [@b0170]2\
Low\
ModerateOS-PCFranceGeriatric Ward -- Short StayGeriatric Patients, HWs, contactsWearable sensors for 6 daysHWs (n = 46)\
Patients (n = 29)\
Contacts (n = 14,037)Detection of close contact between HWs, patients, or contacts combined with time in contact to measure riskSuggests yes, but unclearPagani [@b0175]3\
ModerateOutbreakSwitzerlandGeriatric HospitalSuspected cases - Geriatric patients and HWs of nosocomial outbreakEpidemiology/molecular typingN = 155 suspected casesRespiratory virus molecular testing and sequencing to determine nosocomial transmission patternsUC, HWs not directly causeVoirin [@b0180]3\
ModerateReviewmixedHospital28 nosocomial influenza outbreak reportsn/a; ORION checklist28 outbreaksTransmission of influenza by HWs to patients and as index casesYes in 10 studiesRidgeway [@b0185]2\
Low\
ModerateOS-PCUSAUniversity HospitalDifferent types of healthcare professionalsTemporary mandatory flu testing in HWsHWs (n = 449)% influenza positive HWs by vaccination status; % influenza positive symptomatic HWs vs. asymptomaticUC, but 50% of flu positives were\
asymptomaticKay [@b0190]2\
Low\
ModerateOutbreakUSAHospital retreat facilityHWs attendees and facilitators of a retreatEpidemiology/viral testingHWs (n = 32)\
Facilitators (n = 14)Viral load changes and returning to work, shedding and duration, the association with symptoms and feverUC, but 75% of flu + HWs returned to work whilst illRodriguez-Sanchez [@b0195]2\
Low\
ModerateOutbreak of H1N1SpainClinical Microbiology/infectious Diseases UnitHospitalized patients with confirmed H1N1 influenza (HIV + and non-HIV + )n/a; genetic sequencingHIV + patients (n = 49), Non-HIV+ (n = 37)Phylogenetic trees, outbreak-specific substitutions, and viral variants in infected patientsUC on the source of outbreakValley-Omar [@b0200]3\
ModerateOS-PCSouth AfricaHospital pediatricNosocomial outbreak of H1N1 and children admitted to pediatric ward over 4 monthsEpidemiology/viral sequencing14 casesNosocomial transmission chains and infection sources using phylogenetic analysesYes, transmission with HWs, asymptomatic patients, and visitorsMelchior [@b0205]2\
Low\
ModerateOS-PCBrazilUniversity hospitalHIV + patients, children, contacts, and HWsFlu testing in risk groupsN = 400Prevalence of influenza infection by risk group; influenza + asymptomatic; influenza acquisition by contactsUC  Dini [@b0055]\*4\
High\
ModerateReviewMixed6 systematic reviews/28 studiesInfluenza VaccineNot pooledLab-confirmed flu, ILI, absenteeism, NNV**Does vaccination in HWs benefit patients? Yes/No?**UC benefitRiphagen-Dalhuisen [@b0125]4\
High\
ModeratecRCTThe NetherlandsHospital wardInternal medicine and pediatric department HWs of cRCTInterventions to increase uptakeRates of nosocomial transmission retrospectively as a secondary outcome by internal medicine or pediatric wardYesSeal [@b0210]\*2\
Low\
ModerateReviewMixed1 systematic review of systematic reviews and 2 non-randomised studiesInfluenza vaccine in HWsAll-cause mortality, clinically suspected influenza, vaccine efficacy, working days lost, others hospitalization of patients.NoAmodio [@b0215]2\
Low\
ModerateCS-RCItalyHospitalAcute care hospitalized patientsInfluenza vaccine in HWsN = 62,343 patients\
185 nosocomialInfluenza vaccine coverage, nosocomial ILI and the association between the twoYesBlanco [@b0220]Can't scoreModelUSAHospitalHypothetical hospital in Michigan5 influenza preventions700 patients% reduction of hospitalized flu cases due to each interventionYes assumedShugarman [@b0225]2\
Low ModerateOB-surveyUSANursing FacilitiesNursing facilities (nurses = 301)Influenza vaccine301Effect of resident and staff influenza immunization rates on the likelihood of ILI clusters.Yes (ILI)  Dionne [@b0230]2, Low ModerateOS-RCSUSA550 bed\
HospitalFlu + Hospitalized patients over 5 flu seasonsInfluenza vaccine in HWs533 influenza + nosocomial cases over 5 yearsProportions of nosocomial cases among HWs and patients .Nosocomial influenza rate with lab-confirmed influenza confirmation**How many HWs need to be vaccinated if there is a benefit?**\
**NNV or rangeNo** association; but some reduction in up to 50% vaccine coverage in HWsSalgado [@b0235]3, ModerateOS-RCSUSA600 bed HospitalHospitalized patients in a 600-bed tertiary hospital over 12 yearsInfluenza vaccine in HWsN/AProportions of nosocomial cases among HWs and patients**Yes**, significant proportionate association between vaccine coverage in HWs and a reduction in nosocomial infectionsVan den Dool '09 [@b0240]Can't scoreModelThe NetherlandsSimulation of 24 bed ward hospitalNursing home model applied to a general hospital ward patients and HWsInfluenza vaccine in HWsN/AAssociation of HW vaccination and influenza infections prevented in patients**Yes,** 40% prevention when 100% of HWs vaccinated. NNV = 3Van den Dool '08 [@b0245]Can't scoreModelThe NetherlandsSimulation of Geriatric nursing homeNursing home model with 30 bedsInfluenza vaccination coverage HWsN/AAssociation of HW vaccination and influenza infections prevented in patients; herd immunity**Yes,** 60% prevention when 100% of HWs vaccinated. NNV = 7Wendelboe 2011 [@b0250]3\
ModerateCS-PCUSAGeriatric, long-term care facilitiesResidents and HWs of 75 LTCFs with and w/o outbreaks over two flu seasonsVaccination coverage in HWsN = 21 lab confirmed residents\
N = 40 ILI residentsOdds ratio of outbreak LTCFs by vaccination coverage of HWs - Lab-confirmed influenza or ILI symptoms**Yes,** proportionate prevention of outbreaks with rising vaccination coverageWendelboe 2015 [@b0255]Can't scoreModelUSAGeriatric, long-termResidents and HWs of 76 LTCFs over one flu seasonVaccination coverage in HWsN/AHerd immunity; HW vaccination and probability of influenza in LTCF residents**Yes,** Inverse association[^3][^4]Table 4Rapid Evidence Appraisal included studies and their characteristics for **Topic 3 - Questions 1 & 2.***StudyQualityDesign\# of participants or \# of included studiesCountryPopulationInterventionQuestion 1 Results*\
*What are the successful and practical interventions which increase HW influenza vaccine uptake?*Dini 2013 [@b0055]4\
Moderate\
HighReview7 systematic reviewsMixed7 systematic reviews evaluating\
 \> 200,000 subjectsInterventions to increase uptake in HWsMandatory vaccination is most effective; soft mandates also effective; multi-faceted, complex/integrated programmes effectiveRiphagen-Dalhuisen 2013 [@b0125]5\
HighcRCTN = 13,830The NetherlandsAll employees working in **6 University medical centre**s over two influenza seasonsPre-intervention survey and model to develop interventionInfluenza vaccine coverage significantly higher in intervention groups (seasonal 32.3% vs. 20.4%; pandemic vaccine 61.7% vs. 38%)Hollmeyer 2013 [@b0260]5\
HighSystematic review24 included studiesmixedHWs from acute care hospitals between January 1990-December 2011Interventions to increase uptake in HWsIncreases in vaccine uptake due to free and easy access to vaccine; education and behavior modification (education, incentives or reminders); must create culturally-relevant interventionsAbramson 2010 [@b0265]5\
HighcRCT13 clinics, 163 HCWsIsraelStaff with direct patient contact in **primary car**e community clinics in Jerusalem over 2007--2008 influenza seasonHMO recommendation for vaccination of HWsImmunisation rate 52.8% in the intervention group vs. 26.5% in the control group. Absolute increase since previous year was 25.8% in intervention clinics vs. 6.6% in the control clinicsChambers 2015 [@b0270]4\
Moderate\
HighRCTIntervention group = 13, controls = 13Canada26 healthcare organizations across 6 provinces over two flu seasonsA successful influenza guide vs. nothing newIntervention improved HW vaccination rates, but these rates continued to be sub-optimal and below rates achievable in programs requiring personnel to be immunisedChambers 2012 [@b0275]4\
Moderate\
HighRCTN = 151CanadaNon-vaccinated HWs at 6 weeks of influenza campaign in a healthcare centre (hospital, long-term, mental health)Ottawa Influenza Decision Aid (OIDA)It appears that the OIDA increases confidence in vaccination decision but does not increase odds of intending to be immunisedECDC 2013 [@b0280]3\
ModerateReview5 included studiesEuropean regionStudies on the drivers and barriers to influenza vaccination/coverage in EuropeInterventions to increase uptake in HWsNon-hospital settings: campaigns w/ more components, education/promotion and improved vaccine access increased uptake. Only mandatory vaccine could raise uptake above 90%Europe WHO 2015 [@b0285]Policy toolkitEvidence-based policy guide/toolkit36 included studiesMixedGuidance on increasing HW influenza uptake; literature reviewStudies of the determinants of vaccine uptakeDevelopment of practical guide-*Tailoring Immunization Programmes for Seasonal Influenza* (TIP FLU)- categorizes vaccination decision making by behavioural determinants (personal, social/community, environmental, contact with HWs)Europe WHO 2015 [@b0290]3\
ModerateReview35 included studiesMixedReview to provide examples to countries of successful and replicable interventions to increase uptake in HWsInterventions to increase uptake in HWsMost successful interventions include multiple components; important to increase demand through changes in policy, legislation, and legislation; HWs need burden and risk dataMacdonald 2013 [@b0295]4\
High\
ModerateSystematic literature review22 included evaluationsEuropean regionReview of 22 evaluation **studies in Europe** of promotional communication interventionsPromotional communications for flu in EuropeThey found that all forms of communication can stimulate HW vaccine uptake; promotional communications that target HWs can also improve uptake among patientsStuart 2012 [@b0300]4\
High\
ModerateReview11 included studiesAustralia11 studies on seasonal influenza uptake rates of **Australian HWs,** determinants and strategies to increase uptakeInterventions to increase uptake in HWs/determinantsFactors contributing to immunisation in Australia show only minor variations from international samples. Not enough quality evidence on effective strategies in Australian and globally  *StudyQualityDesign\# of participants or \# of included studiesCountryPopulationInterventionQuestion 2 Results*\
*What are the sociological, behavioural, and public health policy aspects of influenza vaccine uptake in HWs?*Dini 2018 [@b0055]4\
High\
ModerateReview16 included systematic reviewsMixedEvaluating vaccination determinants, vaccine adherence or knowledge or beliefs about vaccine in HWsmixedTopic has been extensively studied under different categories; higher knowledge among medical doctors/more favorable perception; Risk perception influences uptake; variations in uptake by HWLorenc 2017 [@b0305]4\
High\
ModerateSystematic review25 included studiesMixedEvaluating studies of qualitative evidence on HW vaccine uptakemixedMany beliefs are barriers to vaccine uptake- risk beliefs about influenza, vaccine effectiveness, concern about side-effects. Uptake influenced by HWs relationship to employer and feeling autonomousOfstead 2017 [@b0310]4\
High\
ModerateIntervention study and surveyN = 726USAVaccinated and unvaccinated LTCFs' nursing staff from 4 LTCFs in the MidwestEcological model vs. health/belief model to increase uptakeVaccination rates among LTCF HWs and their family members increased significantly, and absenteeism decreased after the implementation of a multifaceted ecological model[^5]Table 5Rapid Evidence Appraisal summary of findings table for all questions.Review Question\# of individual studies included by question\# of Higher Quality studies (Maryland Quality Score ≥ 4)Settings Populations or\# of studies includedMain findingsLimitations of included studiesFuture Considerations**Topic 1**\
**Question 1**\
*Are HWs at an increased risk of influenza infection?*71 study\
A Comprehensive review which evaluates systematic reviews addressing this question.-Hospital settings with different occupations such as physicians, nurses, close patient contact or less patient\
-H1N1 risk and Seasonal influenza risk\
-Patients and HWs during outbreaks**-Yes, in some cases, HWs are at an increased risk, but not always**\
-H1N1pdm09 risk to HWs is clearer than seasonal influenza\
-Risk can vary by occupation with H1N1pdm09 but unclear for seasonal influenza\
-Influenza risk appears to vary year to year depending on virus circulation\
\--Difficult to look across multiple studies to draw conclusions unless controlling for study year, circulating virus, patient populations, health worker type or occupation\--Pooled data may lead to inaccurate conclusions\
-Publication and selection Bias\
-Use of indirect measures of influenza\
-Use of seasonal influenza elements for pandemic models-Research to validate variability in risk with influenza by year, virus, occupation, setting, patient populations\
- Consideration of this variability in risk as an inherent part of research or policy development  **Topic 1**\
**Question 2**\
*Does influenza vaccination benefit HWs or their employers?*144 studies\
2 reviews,\
2 RCTs-Hospital settings\
-University medical centres\
-Staff and students of Dental Faculty\
-Trivalent vaccine\
-H1N1pdm09 vaccine**-Yes, vaccine can be cost-saving and reduce influenza burden, but it isn't entirely consistent**\
-Several higher-level studies suggest vaccine efficacy in health workers and cost-savings to employers through reduced absenteeism\
-We identified a total of 5 RCTs to answer this question, 2 not part of recent systematic reviews and had conflicting results\
-One RCT during 2009--2011 found vaccination to increase absenteeism\
-One RCT only used ILI as an outcome measure\
-Vaccine benefit may be greater when considering asymptomatic influenza and the possible impact on transmission-Applying vaccine effectiveness, efficacy, or attack rate of healthy adults to HWs.\
-Self-reported outcomes\
-Non-specific outcomes\
-low circulation of virus confounds vaccine effectiveness-A need for updated high quality RCTs assessing vaccine benefit over time in multiple settings.\
\--Develop research standards for influenza vaccine benefit\
\--Vaccine type may vary findings  **Topic 2**\
**Question 1**\
*Do HWs transmit influenza to patients?*111 study\
Using high resolution contact data detected with sensors-Patients and HWs in Elderly care Hospital Wards\
-In HIV + patients, \--In children\
During Nosocomial outbreaks-**Yes, HWs have been implicated in some transmission events, most frequently among elderly patients**\
-Transmission and introduction can be directly linked to HWs, patients, and community/visitors\--Small sample size in many studies\
-Most studies of moderate quality-Need to better understand the role of asymptomatic infections in transmission\
-Transmission reduction measures need to consider HWs, patients, and outside contacts as a continuum\
-Need larger studies over a longer duration using high-resolution contact data  **Topic 2**\
**Question 2 Part A**\
*Does influenza vaccination in HWs benefit patients*62-Long-term care facilities in patients -Acute Care facilities\
-Internal Medicine\
-Pediatrics-**Maybe** - **evidence continues to suggest a benefit on protection against all-**cause mortality to LTCF patients\
-Evidence is mixed in other populations, but one RCT in the Netherlands suggests a reduction in nosocomial infection in internal medicine wards, not pediatrics\
-Very few newer RCTs evaluating patient benefit\
-Several studies evaluate ILI rather than lab-confirmed as a measure of benefit-Decisions based on 4 highly biased RCTs in long-term care facilities due to attrition rate, no blinding, contamination in control groups, low rates of vaccination coverage-Need updated cRCTs which span years\
-Need standardized approaches/population to answering this question\
-Patient benefit variations need to be understood and appreciated (more benefit to more vulnerable patients)  **Topic 2**\
**question 2 Part B**\
*How many HWs need to be vaccinated (NNV) to ensure a benefit to patients?*60-Long term care facilities\
-Medical Centre hospital\
-Tertiary Hospital-**NNV range from 3 to 50**\
-Appears to be a benefit in LTCFs when 100% of HWs are vaccinated with the possible prevention of 60% of infections\
-Appears to be a proportional benefit with a greater reduction in nosocomial transmission with higher coverage\
-Appears to be a curvilinear relationship between rising coverage and reduction in nosocomial infections that can be impacted by visitors or other contact elements-Vaccine effectiveness for HWs based on that for healthy adults\
-Other assumptions in models may lead to inaccurate conclusions\
-Outcome definitions in models significantly impacted whether herd immunity could be induced-NNV estimates need to factor in differences in outcome measures used\
-Need to expand body of knowledge beyond geriatric populations which may skew the total findings\
-Need to develop HW vaccine efficacy and attack rate standards for models  **Topic 3**\
**Question 1**\
*What are the successful and practical interventions which increase HW influenza vaccine uptake?*108-Primary care community clinics\
-Acute care hospital staff\
-HWs in tertiary hospitals\
-HWs with and w/o patient contact\
-All personnel of a health institution-**Mandatory Vaccination to be able to work remains the most successful intervention to increase uptake**\
-Other successful interventions are:•Multi-faceted including many elements together (the more the better)•Sustain over time•Provide free and easy access to vaccine•Use behavior change components (reminders, incentives, education)•Develop targeted multi-faceted interventions using baseline data collection to identify barriers in that population•Vaccine promotion from highest levels•Having a vaccine organizer from inside•Opt-out programs (declination statements, required mask use, flu-safe zones)-Appears that intervention success is linked in some respects to the number of interventionsPublication bias considering studies that were not effective may not be published\
-Selection bias as some may not have reported baseline vaccine uptake before intervention\
-Lack of blinding in RCTs\
-Hard to separate the benefit of one intervention as distinct from the others when a part of multi-faceted interventions-Clear guidance needed on vaccine program implementation in HWs which clarify the options of mandatory policy options vs. other.\
-Develop a standardized checklist of components critical for vaccine uptake success\
- Develop guidance on how to develop targeted interventions catering to the individual context for implementation  **Topic 3**\
**Question 2**\
*What are the* sociological*, behavioural, and public health policy aspects of influenza vaccine uptake in HWs*?33-Long-term care facilities\
- Mixed hospital settings of HWs\
-Mixed outpatient settings of HWs**-Strongest barriers to uptake were HW's lack of confidence about disease severity or vaccine effectiveness and a lack of professional or ethical obligation to get vaccinated.**\
-Strongest reason to vaccinate was to protect oneself and not patients\
-Success of a vaccination program may be influenced by the complex relationship between HWs and the organization and management of the health care system within which they work.\
-Ecological model shows promise an alternate to the widely used health belief model-Limited use of models other than Health Beliefs Model-Greater diversity of study approaches to reframe issues through alternative lenses\
-Need to integrate HW influenza vaccine programs into existing programs to ensure long term\
-Need to expand discussion on the importance of top-down support for vaccine programs in HWs to develop a culture of vaccination\
-Need to have a better understanding of the influenza of management /organizationl structures where implementation will take place

3. Literature search results {#s0030}
============================

3.1. Identified literature {#s0035}
--------------------------

The collective literature search identified 3,784 publications, of which 52 individual publications met the inclusion criteria *(see* [Fig. 1](#f0005){ref-type="fig"}*).* Some publications addressed multiple questions resulting in a total of 60 references cited for all questions combined *(see* [table 1](#t0005){ref-type="table"}*).* Of the 60 included studies, we identified 7 RCTs, 24 observational studies, 16 reviews (non-systematic or systematic), and 13 "other" study types (*see* [Fig. 2](#f0010){ref-type="fig"}*A and B*). Individual studies and systematic reviews were excluded from the final list of included studies *(*[Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}*)* when they formed part of a more recent systematic review. These removed studies were still considered in the text if they are of moderate to high quality.Fig. 1Flow Diagram of the literature search strategy, study removal and selection by topic.Fig. 2(A and B). % Distribution of different study types included in our review and % distribution of included studies by Maryland Scientific Methods Quality Scale. (A) % Distribution of Included Study Types by Topic and Question illustrates the limited number of randomized-controlled trials. (B.) % Distribution of Included Studies by Maryland Scientific Methods Quality Scale illustrates the limited number of high-quality studies identified.

3.2. Evidence by topic and question ([Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}) {#s0040}
---------------------------------------------------------------------------------------------------------------------------------------------------

**Topic 1 Question 1** - *Are HWs at an increased risk of influenza infection?*

We identified only 1 higher quality study (4 or higher score) for this question. The review by Dini et al. [@b0055] included 28 studies (12 systematic reviews, 13 *meta*-analyses, 3 appraisals) and addressed several aspects relevant to influenza vaccination in HWs, including laboratory-confirmed incidence and risk compared to controls. The review included a higher level systematic review and *meta*-analysis on the occupational risk of pandemic H1N1 in HWs compared to the general population or across occupations. This *meta*-analysis [@b0315] evaluated 15 studies (29,358 subjects), including 11 high quality studies of laboratory-confirmed influenza, and showed a significantly increased OR = 2.08 (95% CI, 1.73--2.51) in HWs with a higher risk in physicians {OR = 6.03 (95% CI, 2.11--17.8)}.

Kuster et al. [@b0320], a systematic review also included in Dini et al, compared data on influenza infection rates in HWs and healthy adults from 29 surveys (n = 58,245) over 97 influenza seasons [@b0055]. The review calculated a pooled annual incidence of 18.7% (95% CI, 15.80--22.11) per season in unvaccinated HWs versus 5.44% (95% CI, 3.01--9.84) per season in unvaccinated adults and 6.49% (95% CI, 4.63--9.09) for vaccinated HWs versus 1.20% (95% CI, 0.86--1.68) for vaccinated adults. However, this review [@b0320] concluded the overall effect was driven by asymptomatic rather than symptomatic infections. A German study included as part of Dini et al evaluated ILI incidence combined with pre and post-season influenza serology in HWs and non-HWs [@b0325] and concluded there was no difference in risk of symptomatic or asymptomatic influenza infection in HWs compared to non-HWs [@b0055]. However, HWs were found to have an increased risk of clinically diagnosed acute respiratory infection (OR = 3.0, p = 0.04), and were more likely to have a pre-season antibody titre of ≥ 40 to influenza A/H3N2, indicating the possibility of asymptomatic or subclinical influenza infections.

Five additional studies of differing methodological approach and quality provided conflicting conclusions. Three studies pointed to a higher risk [@b0065], [@b0065], [@b0080] including a pandemic simulation modelling study [@b0065] which suggested a plausible attack rate as high as 60% greater in HWs and a moderate-low quality retrospective study in Hong Kong which suggested a higher H1N1 risk in HWs and an inconclusive result when applied to seasonal influenza [@b0060]. Sartor et al. [@b0080] found HWs at an increased risk of influenza infection in a geriatric hospital, although the study contained fewer than 50 subjects. A moderate quality case-control study in Canada found inconclusive results on the risk of ILI in exposed HWs as did a prospective cohort study in Brazil using lab-confirmed influenza [@b0070], [@b0075].

**Topic 1, Question 2** - *Does influenza vaccination benefit HWs or their employers?*

We identified several higher quality studies for this question. Two reviews compared lab-confirmed influenza in vaccinated HWs vs. controls and found a vaccine efficacy of ∼50--90% and a significant protective effect {Relative Risk(RR) = 0.40 (95% CI, 0.23--0.69)} [@b0090], [@b0330] for HWs. The high quality systematic review by Imai et al. [@b0090] further found a reduced incidence of absenteeism due to ILI {RR = 0.62 (95%CI, 0.45--0.85)}, and a significantly shorter sick leave in the vaccinated group {RR = 0.46 (ILI + lab-confirmed), RR = 0.60 (lab-confirmed)}. The study concluded that vaccination provided a protective effect in HWs and deemed vaccination programs as cost-saving. The widely-cited studies by Kliner et al. [@b0330] and Kuster et al. [@b0320] were included in the appraisal by Dini et al who identified 6 reviews relevant to this question [@b0320], [@b0330], [@b0335], [@b0340], [@b0345], [@b0350] and also concluded that vaccination was protective and potentially cost-saving in HWs [@b0055].

Two contradictory RCTs included a Malaysian study that [@b0140] found reduced absenteeism (12 days vs. 52 in the control group, p = 0.002) and ILI (reduced by 52.6%, p = 0.002) due to vaccination, using all self-reported outcomes. A Dutch RCT [@b0125] actually found an increase in absenteeism in the vaccinated groups {2009/10 (4.6% vs 3.4%); 2010/11 (4.6% vs 3.9%)}, although they attributed the increase to more frequent testing for influenza in the intervention cluster and the study was performed during periods of H1N1pdm09 activity in 2009--2011.

We identified 8 observational studies of moderate to lower moderate quality [@b0095], [@b0100], [@b0105], [@b0110], [@b0115], [@b0130], [@b0135], [@b0150], 5 of which found a vaccine benefit to HWs or employers and 3 which found no benefift or inconclusive results. A study in a large Italian hospital found an increase in absenteeism [@b0095] from 2.99 days/person (outside of flu season) to 5.06 days/person (during flu season), which translated to 11,000 attributable absent days/year. The study also found that vaccinated HWs had fewer excess sick days compared to non-vaccinated HWs (1.45 days/person vs. 2.09). A retrospective study in the United States (4063 subjects) compared absenteeism in mandatory vs. non-mandatory vaccination sites [@b0105] and found that vaccinated HWs had fewer symptomatic days absent {2012/2013, OR = 0.82 (95% CI, 0.72--0.93); 2014/2015, OR = 0.81 (95% CI, 0.69--0.95)} and concluded that mandatory vaccination would reduce symptomatic absenteeism.

Three studies suggested no benefit including a prospective cohort study in Israel [@b0115] which found HWs less likely to develop lab-confirmed influenza, although this finding was not significant. A study in Kenya [@b0130] found vaccinated participants were more likely to develop acute respiratory illness (ARI) and more likely to miss work after vaccination. A large retrospective ecological study [@b0100] evaluated ∼800,000 HWs per year over 4 flu seasons in England and found that a 10% increase in vaccine uptake would lead to a decrease in approximately 0.43 percentage points in the absolute sickness absence rate (from 4.5% to 4.07%), or a 10% relative decrease in the sickness rate. Studies looking at the cost-benefit of vaccination generally found HW vaccination to be cost-saving and of economic benefit from the perspective of the employer [@b0090], [@b0120], [@b0140], [@b0145].

**Topic 2, Question 1 --** *Do HWs transmit influenza to patients?*

Evidence varied widely in methodological approach, yet some findings suggest HWs are at least one of the sources of transmission. We identified moderate to higher quality studies which implicated HWs in some transmission events, particularly in geriatric patients, in acute care settings during flu season [@b0155], [@b0160], [@b0165] and during hospital outbreaks [@b0180]. These studies utilized technologies such as wearable sensors [@b0155], [@b0170], molecular-based subtyping methods [@b0160], or phylogenetic analyses combined with case studies or epidemiology [@b0175], [@b0200]. One retrospective cohort study analyzed routes of transmission among HWs and geriatric patients using molecular-based subtyping methods. The study identified three nosocomial outbreak clusters within one 'outbreak' and found a higher influenza incidence in patients (24%) than in HWs (11%) [@b0160]. A large nosocomial outbreak in a geriatric hospital [@b0175] used detailed case studies combined with phylogenetic analysis to reveal 5 clusters of cases and multiple introductions of community strains into the hospital. Similarly, a study by Valley-Omar et al. [@b0200] in South Africa combined epidemiological investigation with phylogenetic analysis to study influenza transmission chains and the extent of nosocomial transmission over a four-month period within a pediatric hospital. This analysis found that most potential nosocomial infections resulted from multiple introductions of Influenza A into the hospital and suggested transmission between asymptomatic patients, HWs, and visitors.

**Topic 2, Question 2, Part A** -- *Does influenza vaccination in HWs benefit patients?*

We identified two higher quality studies relevant to this question [@b0055], [@b0125], and several lower quality studies using ILI [@b0215], [@b0220], [@b0225] as an outcome measure. The comprehensive review by Dini et al. [@b0055] evaluated 6 systematic reviews [@b0330], [@b0345], [@b0360], [@b0365], [@b0370], [@b0385] and found overall inconclusive results as studies were of moderate but mostly lower quality, evaluated the same 4 RCTs [@b0390], [@b0395], [@b0400], [@b0405], and came to different conclusions. The review included the latest version of a Cochrane Systematic Review by Thomas et al. [@b0370] which evaluated these 4 highly cited RCTs in long term care facilities (LTCFs) [@b0390], [@b0395], [@b0400], [@b0405]. However, different from prior reviews by the same author, this time they excluded all-cause mortality as an outcome measure (only influenza-related outcomes) and found no conclusive evidence of the benefit of HW vaccination to LTCF residents. They also found a low quality of evidence with a high risk of bias. Another systematic review and *meta*-analysis [@b0385] included in Dini et al pooled data from 4 RCTs and suggested a benefit to all-cause mortality {RR = 0.71 (95% CI, 0.59 -- 0.85)} and ILI {0.58 (95% CI, 0.46 -- 0.73)}, but all-cause hospitalization and laboratory-confirmed influenza were not statistically significantly altered [@b0055].

Although we identified 5 higher quality clustered randomized controlled trials (cRCTs) [@b0125], [@b0390], [@b0395], [@b0400], [@b0405] which address this question, only the Dutch trial [@b0125] was not included in prior reviews (per our exclusion criteria), other than in de Serres et al. [@b0365] in the next section, illustrating the need for updated cRCTS. This pragmatic cRCT [@b0125] measured rates of nosocomial infection as a secondary outcome in 2 high risk departments -- pediatrics and internal medicine. Within the higher vaccine coverage groups of the internal medicine departments, nosocomial influenza and/or pneumonia was recorded in 3.9% compared to 9.7% in the control hospitals, respectively (p = 0.015). An increase in vaccine coverage was associated with decreased inpatient morbidity from influenza and/or pneumonia in internal medicine settings, but not in pediatrics.

**Topic 2, question 2, Part B** - *How many HWs need to be vaccinated (NNV) to ensure a benefit to patients?*

We found a limited number of moderate quality observational and modelling studies [@b0230], [@b0235], [@b0240], [@b0245], [@b0250], [@b0255] which suggest that a proportionate effect of HW vaccination is likely, where nosocomial influenza infections decrease with increasing HW vaccination coverage. Salgado et al. [@b0235] conducted a retrospective cross sectional study in a USA tertiary care hospital over 12 consecutive years. HW vaccination rates increased from 4% in 1987--1988 to 67% in 1999--2000 (P \< 0.0001). Proportions of nosocomial influenza cases among employees or patients both declined significantly (P \< 0.0001). Logistic regression analysis revealed a significant inverse association between HW compliance with vaccination and the rate of nosocomial influenza among patients (P \< 0 0.001). The authors reported that surveillance of nosocomial spread and isolation policies remained constant during the study period, but concomitant increase in patient influenza vaccination rates may have contributed to the decrease in nosocomial infections. A nested-case control study [@b0375] included in the review by Seal et al. [@b0210] found that a vaccinated proportion of ≥ 35% of HWs in short-stay units appeared to protect against nosocomial influenza among patients (OR = 0.07; 95% CI, 0.005--0.98) independent of patient age, influenza season and potential influenza source. The authors concluded that a minimum of 35% vaccination coverage in HWs would be required to have a potential protective impact on hospital-acquired influenza infection.

Dini et al. [@b0055] also included a review by de Serres et al. [@b0365] who used the mathematical principal of dilution as the basis for their re-examination of the main 4 cRCTs used as evidence for mandatory vaccine policies in HW [@b0390], [@b0395], [@b0400], [@b0405]. They disputed the NNV (number needed to vaccinate) of 8 found by Hayward in 2006 in LTCF settings [@b0400] and recalculated it to be 36,000, which was quickly disputed by Hayward [@b0410]. Hayward stressed that results from their study in LTCFs were not necessarily applicable outside of the most frail and vulnerable patients.

In two modelling studies by van den Dool et al. [@b0240], [@b0245], one model in LTCFs predicted "a robust linear relationship between the number of HWs vaccinated and the expected number of influenza infections in patients, preventing ∼ 60% of influenza virus infections among patients" (NNV = 7). Comparing these results in LTCFs to a hospital or short stay setting, they found an equivalent or higher estimate of impact in hospital patients (NNV = 3) and that vaccination of 100% of HWs would potentially prevent 40% of inpatient nosocomially acquired influenza infections.

**Topic 3, Question 1**-- *What are the successful and practical interventions which increase HW influenza vaccine uptake?*

We identified several higher quality RCTs and systematic reviews addressing this question and there is consensus that no single intervention component has been found to rapidly and substantially raise influenza vaccination rates in HWs, aside from mandatory vaccination [@b0415]. However, several systematic reviews [@b0260], [@b0295], [@b0420] and tool kits [@b0285], [@b0290] have highlighted that multifaceted approaches which sustain over time can see increases \> 90% [@b0235]. Dini et al. [@b0055] evaluated 7 systematic reviews which together evaluated strategies to increase uptake in HWs in \> 200,000 subjects. They found that some successful alternatives to mandatory vaccination included "soft-mandates", such as masks, "opt-out", or declinations statements, and multi-faceted programmes which take into consideration the local context, include incentives, education, advertising, and easy vaccine access as efforts to enhance behavior change.

Higher level systematic reviews had similar findings including a *meta*-regression analysis that [@b0420] found that the single most successful strategies after mandatory vaccination were "soft" mandate strategies and a policy excluding non-vaccinated HWs from working with highly vulnerable patient groups. Another systematic review [@b0260] found that successful interventions contained the following critical components: free and easy access to vaccine; knowledge and behavior change through educational activities; reminders and incentives; management/organizational approaches including personnel charged with implementing the programme; and a long-term strategy. An additional study of 121 publications also concluded that all interventions increased uptake to some extent with the most successful being those which required vaccination as a condition of being allowed to work [@b0425].

Several randomised trials [@b0430] have successfully used a pre-intervention survey as a basis for subsequent intervention mapping [@b0125], [@b0440] in the development of multi-faceted interventions. This is particularly important as the reasons for vaccine hesitancy are complex and heterogeneous [@b0260], making local, social, cultural, institutional and logistical factors all relevant to the development of educational or knowledge-based interventions. Other RCTs failed to dramatically raise uptake using educational tools or manuals and a decision aide intervention which changed views but not actions [@b0270], [@b0275], [@b0280].

**Topic 3, Question 2** -- *What are the sociological, behavioural, and public health policy aspects of influenza vaccine uptake in HWs?*

We identified 3 higher moderate studies on this topic, including two reviews [@b0055], [@b0305]. One review [@b0055] evaluated 16 systematic reviews on vaccination determinants in HWs, adherence to vaccination, and risk perceptions or beliefs about vaccination. The study broadly found the following: knowledge about influenza varied by occupation, not necessarily occupational level (doctors vs. dentists for example); many misconceptions about influenza persist, even though influenza knowledge has improved over time; the relationship between HWs' perception and mitigation of risk is complex and multi-factorial and needs to be better understood. Included as part of this review was a large systematic review by Schmid [@b0440] which included 470 studies, of which 117 looked at HW barriers to influenza vaccine uptake. Their review found that micro-level determinants included age, gender, additional risk factors, and past behavior as the most reported factors to influence uptake. They further evaluated the determinants based on the 4C model for vaccine hesitancy (complacency, confidence, convenience, and calculation) and found that the strongest barrier to uptake was a HWs lack of confidence about disease severity or vaccine effectiveness and "a lack of professional or ethical obligation to get vaccinated". This was in line with the systematic review by Hollmeyer which found that HWs are motivated to be immunized against influenza more often for their own benefit than for the benefit of their patients [@b0260].

Lorenc et al. [@b0305] conducted a systematic review of 25 studies on HWs' beliefs and perceptions about vaccination within different contexts and found that many participants are unsure of the real value of vaccination programs. This study highlighted that the success of a vaccination program may be influenced by the complex relationship between HWs and the organization and management of the health care system within which they work. Ofstead and colleagues [@b0310] executed a three-part evidence-based intervention study in LTCFs which compared a multi-faceted ecological model and the health belief model. They raised uptake from 50% to 85%, decreased respiratory illness-related absenteeism by 12% and concluded that an ecological model was more effective than the health belief model at increasing uptake as it includes broader policy or organizational aspects relevant to program implementation.

4. Discussion {#s0045}
=============

We executed a *Rapid Evidence Appraisal* [@b0040] of the literature from 2006 to 2018 to evaluate the evidence relevant to the ongoing discussions about seasonal influenza vaccination in HWs. Influenza infection and vaccination in HWs poses a complex policy challenge due to the general lack of high quality evidence, the inherent complexity of influenza, and the number of potential benefactors: HWs themselves by avoiding influenza infection, their patients by virtue of reduced influenza transmission in health facilities, their employers in terms of business continuity, and potentially their families and wider community contacts.

4.1. Influenza risk to health workers {#s0050}
-------------------------------------

The evidence on whether HWs are at increased risk of influenza infection (symptomatic and asymptomatic) in HWs is mixed. Recent studies suggest a higher risk with pH1N1 [@b0055], [@b0060], [@b0065], [@b0315], a high attack rate, and variations in risk which are connected to occupational exposure. Other studies find a risk to patients and HWs during an outbreak [@b0080] and following contact with ILI patients [@b0075]. Additional studies suggest only a risk of asymptomatic infection [@b0085], [@b0320]. Taken together, these studies highlight that setting [@b0450], occupation [@b0455] or patient contact level, risk procedure [@b0460], circulating virus, and existing immunity in the population (i.e. H1N1) can all vary risk [@b0315]. However, respiratory illness has been reported as one of the main causes of sickness absence in HWs [@b0475], [@b0470], pandemics and epidemics can be associated with concurrent increased rates of HW absenteeism [@b0060], [@b0475], [@b0480], and HWs do overall appear to be at risk of contracting influenza.

4.2. Vaccine benefit to health workers or their employers {#s0055}
---------------------------------------------------------

Recent higher level evidence [@b0055], [@b0090] evaluating RCTs, cohort studies, and systematic reviews does suggest a vaccine benefit to HWs and their employers including a protective effect against laboratory-confirmed influenza, shortened sick leave, and a reduced incidence of absenteeism (due to ILI). However, vaccine benefit studies during the years of pH1N1, including an RCT in the Netherlands, found the opposite effect, an increase in absenteeism in the vaccination arms. Different authors draw contradictory conclusions from the use of the same RCTs [@b0485], [@b0490], [@b0495], indicating a need for updated, large scale studies of higher quality. Observational studies also draw different conclusions and are constrained by poor study design, non-specific outcomes, a high risk of bias, and failure to adjust for confounding factors. Absence due to ILI is frequently used as an outcome measure when ILI itself has relatively poor predictive value for influenza infection [@b0500], [@b0505]. Although studies may provide contradictory conclusions, vaccine efficacy in HWs has been shown to be as high as 90% for well-matched seasonal influenza vaccines [@b0330], [@b0340], and high for pandemic vaccine [@b0510]. Therefore, it seems reasonable that vaccinating HWs against influenza will reduce influenza burden in HWs, related work absenteeism, and possibly influence subclinical infection and/or "presenteeism" -- attending work whilst ill.

4.3. Influenza risk to patients {#s0060}
-------------------------------

The expanding volume of studies combining epidemiological and phylogenetic analysis, among other new technologies [@b0355], [@b0360], suggest that HWs are implicated in at least some transmission during nosocomial outbreaks of influenza. However, the complexity of transmission in health facilities is also driven by various factors including patient to patient and visitor to patient contact, varying levels of possible infectiousness with asymptomatic vs. symptomatic transmission, and high patient turnover, particularly in acute care settings [@b0185], [@b0190], [@b0200]. Nevertheless, Pagani et al. [@b0175] identified multiple introductions of strains into the hospital from the community during an outbreak and noted that unvaccinated HWs may have played an important role in sustaining the outbreak. Other factors which may increase or decrease the extent to which HWs are implicated in transmission are individual (immune status, severity of disease, viral shedding), pathogen (virulence, infective dose), and environmental factors (infection control practices, ward layout, frequency of patient, staff and visitor contacts), including contact with HWs of varying degrees of risk exposure themselves. Notwithstanding, the evidence does suggest that HWs can clearly pose a transmission risk to patients, at least some of the time.

4.4. Vaccine benefit to patients {#s0065}
--------------------------------

The benefit of HW influenza vaccination to patients is not clear or consistent in the literature and continues to be debated as numerous systematic reviews using mostly the same RCTs [@b0390], [@b0395], [@b0400], [@b0405] all draw different conclusions [@b0055], [@b0330], [@b0365], [@b0385]. Research in LTCFs has consistently shown a benefit to patients, at least for all-cause mortality. Variations across study populations or studies, such as patient populations, level of HW to patient contact, patient vulnerability or susceptibility, or levels of risk exposure for HWs themselves, limit comparability between findings. This may explain why studies in LTCFs consistently find vaccination of HWs beneficial to elderly patients, where the stability of the setting, patient characteristics, and high level of contact between HWs and patients are all consistent factors. Whereas, a larger body of evidence suggests an unclear association between HW vaccination and patient benefit in hospital settings, which may be due to variations in study design, HW or patient characteristics, their individual risk or susceptibility, difference in vaccine type or diagnostic testing, or even the time of year. LTCF patients do however appear to benefit, at least regarding mortality, which demonstrates that vaccine benefit to patient warrants efforts to increase vaccination in HWs caring for the elderly [@b0515].

4.5. Influenza vaccine uptake {#s0070}
-----------------------------

The factors that feed into a HWs decision-making pathway for influenza vaccination are diverse and individually-driven [@b0260]. Therefore, any efforts must be as equally diverse as the HWs they target. Mandatory vaccination is debated extensively from many perspectives including the reasons for [@b0105] and against it [@b0365]; however, no amount of debate can refute that mandatory vaccine policies do raise uptake quickly, usually to levels in excess of 94--96% [@b0415]. Other successful interventions are multi-faceted, sustained over time [@b0235], and evolve over time as data is collected on the target population [@b0430]. These make vaccine easily accessible, maintain strong organizational support, develop education which varies by targeted groups, and may include "soft-mandate" policies, such as declination statements, or alternatives such as masks [@b0260], [@b0420].

One area which deserves more consideration, is the use of different types of models in the development of interventions to improve uptake. Traditionally, the health belief model is most commonly used. However, studies exploring other possibilities [@b0310], [@b0440] have shown promise with an ecological model, which takes into consideration the contextual, organizational, policy or background components which are relevant to a vaccine program and henceforth to a HWs decision to take the vaccine. These models incorporate the growing understanding that HW vaccine uptake involves much more than individual knowledge, attitudes, and beliefs. The greater context of the HW and their relationship to the organization, other HWs, and broader cultural factors are all important to vaccine uptake.

4.6. Study limitations {#s0075}
----------------------

Although we made every effort to execute an unbiased and systematic approach to our search and selection of included literature, our study was not without limitations. Due to resource and time constraints, we limited the search to English language abstract or full-text articles, did not include grey literature, and removed publications that were included as part of a more recent systematic review. This may have led to some selection bias and limited our exposure to all relevant articles. However, due to the breadth of questions included in the search and the execution of three distinct searches, we felt that this diversification may have added strength to the study design to compensate for this weakness.

The majority of included studies were observational studies, which limits the strength of our findings as observational studies are susceptible to bias and there is limited ability to infer causality. Additionally, many studies were executed in different types of settings, with different target populations, using different vaccines and with varying levels of risk or exposure to the populations being studies. This makes comparing across studies very difficult.

Our methodology lacks the robustness of a formal systematic review or *meta*-analysis and does not report on effect size. Systematic reviews have very defined limitations for study selection and inclusion and typically do not query so many questions. We executed a Rapid Evidence Appraisal - a time-limited effort of assessing the evidence to draw conclusions, a process similar to what might happen in a 'real-life' policy environment. To compensate, we approached the literature search in a systematic way to add robustness to our study design and the breadth of our included questions and consideration of multiple elements relevant to the decision-making process, offers a more realistic approach for policy makers. Finally, our study was adapted and updated from a white paper originally intended to advise and inform WHO when establishing the influenza vaccine research agenda. The objective was to support global policy recommendations.

5. Conclusion (see summary of findings [Table 5](#t0025){ref-type="table"}) {#s0080}
===========================================================================

In recent years, several comprehensive reviews [@b0055], [@b0090], [@b0210], [@b0305], [@b0320], [@b0330], [@b0335], [@b0365], [@b0370], [@b0385], [@b0420], [@b0440], [@b0445] have attempted to rigorously address different aspects of influenza vaccination in health workers. Paradoxically, the number of reviews far outweighs the number of studies that are of high quality or give definitive answers. Similarly, our review included only RCTs that have not already been evaluated as part of a more updated systematic review. It is therefore hardly surprising that it has proved difficult to draw universal and emphatic conclusions for policy makers, government leaders, and healthcare managers; and that implementation is poor and acceptance low.

Nevertheless:•Nosocomial influenza is a recognized problem and it is clear there is a problem to solve or a case to answer.•There is adequate evidence that HWs contract influenza and data suggests they are at risk of continuing to work whilst infected.•There are sufficient data to conclude that influenza vaccines are as effective in HWs as in other adults of similar age.•Data are emerging that capture the complexity of influenza transmission in health facilities and new molecular evidence implicates HWs in transmission events.•Data on whether vaccinating HWs protects patients is of mixed quality and does not universally favor a positive (protective) outcome. However, there are strong signals from studies in LTCFs that HW vaccination protects patients, especially with regard to mortality.

The evidence base requires improvement and future research should aim to evaluate the impact of HW vaccination on clearly defined and standardized outcome measures in specific cohorts of beneficiaries. A better understanding of transmission dynamics across a diversity of HW and patient risk groups is needed to facilitate a more nuanced and useful estimation of the wider benefits of HW influenza vaccination. The large body of knowledge on effective ways to increase vaccine uptake in HWs needs to be incorporated consistently within vaccination policies and practices. Programmes will need to consider the importance of organizational and contextual factors as drivers alongside the individual perceptions of HWs. The evidence demonstrating the effectiveness of mandation in improving uptake is however emphatic.

Influenza is likely to persist as a unique methodological challenge for researchers to produce reliable and robust results which lead to definitive conclusions about HW vaccination. Influenza burden, infectiousness, and severity vary yearly, seasonally, and spatially. Influenza risk also varies by setting, such as in proximity to young children or immune-compromised individuals, and by occupation or activity (such as performing respiratory procedures on infected patients). Additionally, influenza vaccine effectiveness is equally variable by season and subtype, making comparisons between years and populations challenging.

Due to the inherent complexity of influenza, waiting for the perfect results with influenza risks decision paralysis. When considering the evidence with a 'whole-of-system' approach, rather than considering specific evidence questions in isolation, we argue that the case for vaccinating HWs against influenza is maintained. Furthermore, to ensure the success and likelihood of expansion of seasonal influenza programs globally, guidance is needed for policy makers and implementers on how to best integrate influenza vaccination to HWs within existing vaccination and occupational health frameworks.
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